Bruker Corp (BRKR) Stock Price & Analysis
Bruker Corp (BRKR) rose 1.74% to USD 57.24 as of June 10, 2026 at 05:06 UTC, according to Nexqual real-time market data.
BRKR last closed at USD 56.26; the session ranged USD 55.18–58.58 on volume of 2,117,667 shares. Market capitalization is $8.71B, with a 52-week range of USD 28.53–64.54 (NMS). Source: Nexqual, June 10, 2026 at 05:06 UTC.
Key Statistics (as of June 10, 2026 at 05:06 UTC)
| Price | USD 57.24 |
|---|---|
| Change | ▲ 1.74% (up) |
| Previous Close | USD 56.26 |
| Open | USD 57.49 |
| Day Range | USD 55.18 – 58.58 |
| 52-Week Range | USD 28.53 – 64.54 |
| Volume | 2,117,667 shares |
| Market Cap | $8.71B |
| Exchange | NMS |
Technical Analysis (BRKR)
Nexqual's technical model rates BRKR "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:06 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.51 (neutral) |
| vs SMA50 | Above (USD 42.8) |
| MACD | 4.9 (positive) |
Analyst Ratings (BRKR)
Wall Street analysts rate BRKR "Buy" based on 12 analysts, with a mean price target of USD 53.25 (range USD 35–69), per Nexqual as of June 10, 2026 at 05:06 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 53.25 |
| High Target | USD 69 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 8 / 4 / 1 |
Earnings (BRKR)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.38 |
| Revenue Estimate | $853.39M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.31 vs est 0.23 ▲ beat |
| 2025-12-31 | USD 0.59 vs est 0.65 ▼ miss |
| 2025-09-30 | USD 0.45 vs est 0.32 ▲ beat |
| 2025-06-30 | USD 0.32 vs est 0.42 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:06 UTC.
Financials & Fundamentals (BRKR)
| Total Revenue | $3.46B |
|---|---|
| Revenue Growth (YoY) | +2.70% |
| Gross Margin | +47.62% |
| Operating Margin | +6.18% |
| Profit Margin | -0.34% |
| ROE | -0.43% |
| Debt / Equity | 68.12 |
| Current Ratio | 1.55 |
| Total Cash | $133.40M |
| Total Debt | $1.70B |
| Free Cash Flow | $212.49M |
Source: Nexqual, June 10, 2026 at 05:06 UTC.
Financial Health Score (BRKR)
Nexqual rates Bruker Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:06 UTC.
| Growth | Mixed — Revenue +2.1% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 48%, operating 6% |
| Balance Sheet | Solid — $133M cash vs $1.70B debt |
| Cash Flow | Solid — FCF $212M, 6% margin |
| Efficiency | Critical — ROE -0%, ROA 2.7% |
Ownership (BRKR)
| Insider Ownership | +26.95% |
|---|---|
| Institutional Ownership | +92.77% |
| Shares Outstanding | 152.23M |
| Float | 103.57M |
| Short % of Float | +17.41% |
Source: Nexqual, June 10, 2026 at 05:06 UTC.
Leadership (BRKR)
Bruker Corp is led by Frank H. Laukien (age 65), Chairman, CEO & President, per Nexqual as of June 10, 2026 at 05:06 UTC.
| Chairman, CEO & President | Frank H. Laukien (age 65) |
|---|---|
| Executive VP & CFO | Gerald N. Herman (age 66) |
| Corporate Executive VP and President of Bruker Nano Group & Corporate | Mark R. Munch (age 63) |
| President of Bruker CALID Group & Bruker Daltonics Division | Juergen W. Srega (age 70) |
| President of Bruker BioSpin Group | Falko Busse (age 58) |
Major Backers & Investors (BRKR)
Notable institutional backers of Bruker Corp include Orbis Allan Gray Ltd, FMR, LLC, Pallas Capital Advisors Llc, according to Nexqual as of June 10, 2026 at 05:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbis Allan Gray Ltd | 11.79% |
| FMR, LLC | 10.58% |
| Pallas Capital Advisors Llc | 6.23% |
| Fidelity | 3.26% |
| Edmond De Rothschild Holding S.A. | 2.21% |
| Sculptor Capital LP | 2.15% |
| Franklin Resources, Inc. | 1.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.22% |
| BlackRock | 9.8% |
| State Street | 2.57% |
Source: Nexqual, June 10, 2026 at 05:06 UTC.
From Bruker Corp's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, we are required to comply with the FDA's Quality System Regulation, which sets forth the good manufacturing requirements for medical devices.
- Our technology platforms include magnetic resonance, mass spectrometry, gas and liquid chromatography, X-ray, microscopy, metrology, and molecular spectroscopy technologies.
- This level of investment in research and development has historically exceeded the industry average and reflects our commitment to scientific research and technological advancement to provide innovative products and solutions to our customers and maintain our competitive advantage.
Partnerships
- BEST has an ongoing collaboration and a joint technology development agreement with Allegheny Technologies Incorporated to advance state-of-the-art niobium-based superconductors, including those used in MRI magnets for the medical industry, and preclinical MRI magnets used in the life-science tools industry.
- Our research and development efforts are conducted for the relevant products within each of the operating segments, as well as in collaboration with others on areas such as microfluidics, automation and workflow management software.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIO | Bio-Rad Laboratories, Inc. | USD 297.17 | ▲ 0.97% |
| CRL | Charles River Laboratories Inte | USD 189.85 | ▲ 4.69% |
| ICLR | ICON plc | USD 151.82 | ▲ 1.59% |
| WAT | Waters Corporation | USD 371.15 | ▲ 1.58% |
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:06 UTC. This page is informational and not investment advice.